Artis BioSolutions

Lake Nona, FL
Cell Therapy CAR-T
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
59.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (2)

Quick Facts: Artis BioSolutions

Signal Score
59.0/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Lake Nona, FL
Modalities
Cell Therapy, CAR-T
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCell Therapy, CAR-T
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 58.0
1 CGT manufacturing site: Lake Nona, FL
Modalities: Cell Therapy, CAR-T
Capacity assessment: 58.0/100
Sites: Lake Nona, FL
Source: SEC EDGAR, press monitoring, company profiles
1 CGT manufacturing site
Recent Press2 articles
1 CGT manufacturing site: Lake Nona, FL
Modalities: Cell Therapy, CAR-T
Capacity assessment: 58.0/100

Recent News 2 articles

general 2026-03-05
Forma Life Sciences launches with oral solid dose focus, joining class of new CDMOs - Fierce Pharma
Forma Life Sciences launches with oral solid dose focus, joining class of new CDMOs  Fierce Pharma
Source →
general 2026-02-17
Artis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA Strategy - Business Wire
Artis BioSolutions Appoints Dr. Kate Broderick, Ph.D., as Chief Scientific Innovation Officer to Advance Synthetic DNA Strategy  Business Wire
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs → CAR-T CDMOs →